Related Experiment Video
Updated: May 21, 2026
10:52
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
Published on: December 17, 2010
[Lymphocytic hypophysitis due to ipilimumap therapy]
1Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C, Denmark. hehoth@gmail.com
Ugeskrift for Laeger
|June 28, 2012
Summary
Ipilimumab improves survival in malignant melanoma by stimulating the immune system. However, serious side effects like hypophysitis and severe diarrhea can occur, requiring prompt medical attention.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Ipilimumab is an immunotherapy drug that enhances the immune response against cancer.
- Malignant melanoma treatment has been significantly improved by ipilimumab, increasing survival rates.
- While generally safe, ipilimumab can cause immune-related adverse events.
Observation:
- This report details two cases of severe adverse reactions to ipilimumab.
- One case involved hypophysitis, an inflammation of the pituitary gland.
- The second case presented with severe diarrhea during glucocorticoid therapy for hypophysitis.
Findings:
- Hypophysitis and severe diarrhea are potential serious adverse events associated with ipilimumab therapy.
- These reactions necessitate careful monitoring and management.
- Early diagnosis and intervention are crucial for preventing potentially fatal outcomes.
Implications:
- Healthcare professionals must be vigilant for immune-related adverse events during ipilimumab treatment.
- Prompt recognition and management of side effects like hypophysitis and severe diarrhea are essential.
- Multidisciplinary collaboration is required for optimal patient care and follow-up.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...